Who Paid My Doc
Jacob Mendenhall
Dentist, Oral and Maxillofacial Surgery Oklahoma City, OK Doctor of Dentistry
NPI 1033252937 CMS profile 274197
10900 Hefner Pointe Dr, Suite 204, Oklahoma City, OK 73120
General payments
$7,579
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jacob Mendenhall of Oklahoma City, OK is reported in the CMS Open Payments database as having received $7,579 across 65 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 93rd percentile of Dentist, Oral and Maxillofacial Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $4,934 | 8 | |
| 2024 | General | $345 | 7 | |
| 2023 | General | $835 | 14 | |
| 2022 | General | $611 | 11 | |
| 2021 | General | $285 | 14 | |
| 2020 | General | $125 | 4 | |
| 2019 | General | $443 | 7 |
Beside peers
- Jacob Mendenhall
- Dentist, Oral and Maxillofacial Surgery median
- Middle half of Dentist, Oral and Maxillofacial Surgery
- National median
In program year 2025, general payments to Jacob Mendenhall were reported at $4,934. Among 3,834 Dentist, Oral and Maxillofacial Surgery profiles paid that year, the median was $150 and the middle half received between $56 and $423.
Show as a table
| Year | Jacob Mendenhall | Dentist, Oral and Maxillofacial Surgery median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $443 | $142 | $50–$420 | $163 |
| 2020 | $125 | $96 | $36–$277 | $114 |
| 2021 | $285 | $138 | $45–$419 | $132 |
| 2022 | $611 | $144 | $48–$367 | $149 |
| 2023 | $835 | $153 | $55–$399 | $160 |
| 2024 | $345 | $152 | $50–$400 | $164 |
| 2025 | $4,934 | $150 | $56–$423 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 6 drugsPart D claims
545
Drug cost
$1,470
Branded share of claims
49.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Amoxicillin | Generic | 200 | $469 | |
| Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen | Brand | 172 | $392 | |
| Ondansetron Odt Ondansetron | Brand | 98 | $349 | |
| Azithromycin | Generic | 22 | $113 | |
| Chlorhexidine Gluconate | Generic | 23 | $96 | |
| Tramadol Hcl | Generic | 30 | $50 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 5,440 Part D prescribers listed as Oral Surgery (Dentist only); they describe a distribution and say nothing about conduct.
Records
65 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Related records
Dentist, Oral and Maxillofacial Surgery in Oklahoma
Practitioners in the same specialty and state, ranked by reported value.
All Dentist, Oral and Maxillofacial Surgery
Everyone recorded under this specialty, nationwide.
Doctors in Oklahoma
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.